Nanjing Pharmaceutical Factory Co. Ltd. was initially found in 1935 and was one of the key manufacturers in National Pharmaceutical Industry. After the asset reorganization by Shenzhen Anyuan Investment Group in 2000, Nanjing Pharmaceutical Factory becomes a large scaled pharmaceutical group that integrates R&D, production and marketing of APIs (Active Pharmaceutical Ingredients), formulations and intermediates. The new management adjusts the product line and company’s development strategy, Abiding by the “care for life, commit to health” philosophy, Nanjing Pharmaceutical Factoty will unswervingly make greater contributes to improve the quality of human’s life and health under the guidance of “reform and innovation”.
The APIs manufacturing base, locating in Nanjing Chemical Industrial Park, has six production plants including special and multi-purpose workshops. The base has passed both national and international official GMP inspection many times. Nearly twenty kinds of APIs are sold to domestic and overseas markets.
The formulations manufacturing base locates in Nanjing Xingang Economic & Technological Development Zone, with injection workshop (antineoplastic agents-based powder and water injections) and solid oral preparation workshop (tablets, capsules and granules). The base has passed the national GMP inspections many times. More than twenty kinds of preparations are sold all over China.
All API and Finished Dosage products have passed Chinese SFDA inspections with regulatory approvals. Sucralfate API passed US FDA inspection since 1995. Praziquantel API passed US FDA inspection since 2002, with EDQM CEP approval since 2008.